41270-96-6
41270-96-6 structure
- Name: 4-IPP
- Chemical Name: 4-Iodo-6-phenylpyrimidine
- CAS Number: 41270-96-6
- Molecular Formula: C10H7IN2
- Molecular Weight: 282.08000
- Catalog: Research Areas Metabolic Disease
- Create Date: 2017-09-01 01:09:03
- Modify Date: 2025-09-14 14:06:47
-
4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF)[1].
| Name | 4-Iodo-6-phenylpyrimidine |
|---|---|
| Synonyms |
4-Jod-2-methyl-6-nitro-anilin
iodomethylnitroaniline 4-iodo-2-methyl-6-nitro-aniline 4-iodo-6-phenyl-pyrimidine 4-iodo-2-methyl-6-nitrobenzenamine 4-iodo-6-methyl-2-nitroaniline 5-Jod-3-nitro-2-amino-toluol |
| Description | 4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF)[1]. |
|---|---|
| Related Catalog | |
| Target |
MIF[1] |
| In Vitro | 4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity[1]. 4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes[1]. 4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation[1]. 4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner[1]. 4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption [1]. Cell Cytotoxicity Assay[1] Cell Line: BMMs Concentration: 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM Incubation Time: 24 hours, 72 hours Result: Inhibited osteoclastogenesis in a dose-dependent manner. Western Blot Analysis[1] Cell Line: BMMs Concentration: 5 μM,10 μM, 20 μM Incubation Time: 1 day, 3 days, 5 days Result: Inhibited RANKL-induced osteoclast differentiation and bone resorption. |
| In Vivo | 4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation[1]. Animal Model: 8-weeks-old C57BL/6J male mice[1] Dosage: 1 mg/kg, 5 mg/kg Administration: Intraperitoneal injection; every 2 days; for 8 weeks Result: Alleviated OVX-induced osteoporosis. |
| References |
| Density | 1.728±0.06 g/cm3 |
|---|---|
| Boiling Point | 380.2±30.0 °C |
| Molecular Formula | C10H7IN2 |
| Molecular Weight | 282.08000 |
| Exact Mass | 281.96500 |
| PSA | 25.78000 |
| LogP | 2.74820 |
| Storage condition | -20°C |
| Symbol |
GHS05, GHS07 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H302-H315-H318-H335 |
| Precautionary Statements | P261-P280-P305 + P351 + P338 |
| Hazard Codes | C |
| RIDADR | NONH for all modes of transport |